Antibe Therapeutics Inc.
ATBPF
$0.2156
$0.025613.47%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 15.63% | 18.45% | 23.09% | 26.01% | 20.74% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -132.73% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -56.77% | -52.77% | -40.91% | -46.37% | -50.55% |
| Change in Net Operating Assets | -186.11% | -140.20% | -81.61% | -97.74% | -94.83% |
| Cash from Operations | -5.34% | -14.65% | 6.79% | 8.43% | -399.36% |
| Capital Expenditure | 116.85% | 7.04% | 7.04% | 7.04% | -41.27% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | 100.00% |
| Divestitures | 13.11% | -- | -- | -- | -- |
| Other Investing Activities | 153.93% | 124.04% | 118.31% | 39.83% | -- |
| Cash from Investing | 156.71% | 124.95% | 119.20% | 42.00% | -12,351.97% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 99.15% | 99.35% | 74.03% | 48.03% | 22.00% |
| Issuance of Common Stock | -- | -- | -- | -- | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 16,100.00% | -- | 8,050.00% | 8,050.00% | -100.02% |
| Cash from Financing | 227.83% | 196.21% | 500.92% | 366.04% | -100.31% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 101.46% | 80.97% | 80.74% | 26.86% | -210.70% |
